BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Wang S, Han C, Pae C. Criticisms of drugs in early development for the treatment of depression: what can be improved? Expert Opinion on Investigational Drugs 2015;24:445-53. [DOI: 10.1517/13543784.2014.985784] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
Number Citing Articles
1 Baldessarini RJ, Forte A, Selle V, Sim K, Tondo L, Undurraga J, Vázquez GH. Morbidity in Depressive Disorders. Psychother Psychosom 2017;86:65-72. [DOI: 10.1159/000448661] [Cited by in Crossref: 30] [Cited by in F6Publishing: 31] [Article Influence: 7.5] [Reference Citation Analysis]
2 Han C, Wang SM, Bahk WM, Lee SJ, Patkar AA, Masand PS, Mandelli L, Pae CU, Serretti A. A Pharmacogenomic-based Antidepressant Treatment for Patients with Major Depressive Disorder: Results from an 8-week, Randomized, Single-blinded Clinical Trial. Clin Psychopharmacol Neurosci 2018;16:469-80. [PMID: 30466219 DOI: 10.9758/cpn.2018.16.4.469] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 4.0] [Reference Citation Analysis]
3 Han C, Wang SM, Lee SJ, Jun TY, Pae CU. Optimizing the Use of Aripiprazole Augmentation in the Treatment of Major Depressive Disorder: From Clinical Trials to Clinical Practice. Chonnam Med J 2015;51:66-80. [PMID: 26306301 DOI: 10.4068/cmj.2015.51.2.66] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.5] [Reference Citation Analysis]
4 Wang XL, Feng ST, Wang YT, Chen NH, Wang ZZ, Zhang Y. Paeoniflorin: A neuroprotective monoterpenoid glycoside with promising anti-depressive properties. Phytomedicine 2021;90:153669. [PMID: 34334273 DOI: 10.1016/j.phymed.2021.153669] [Reference Citation Analysis]
5 Lee KH, Bahk WM, Lee SJ, Serretti A, Pae CU. A Practical Utility and Benefit of Pharmacogenetic-based Antidepressant Treatment Strategy for Major Depressive Disorder Patients with Difficult-to-treat. Clin Psychopharmacol Neurosci 2021;19:160-5. [PMID: 33508800 DOI: 10.9758/cpn.2021.19.1.160] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
6 Partyka A, Jastrzębska-więsek M, Antkiewicz-michaluk L, Michaluk J, Wąsik A, Canale V, Zajdel P, Kołaczkowski M, Wesołowska A. Novel antagonists of 5-HT6 and/or 5-HT7 receptors affect the brain monoamines metabolism and enhance the anti-immobility activity of different antidepressants in rats. Behavioural Brain Research 2019;359:9-16. [DOI: 10.1016/j.bbr.2018.10.004] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
7 Wang SM, Han C, Lee SJ, Jun TY, Patkar AA, Masand PS, Pae CU. Second Generation Antipsychotics in the Treatment of Major Depressive Disorder: An Update. Chonnam Med J 2016;52:159-72. [PMID: 27689026 DOI: 10.4068/cmj.2016.52.3.159] [Cited by in Crossref: 31] [Cited by in F6Publishing: 27] [Article Influence: 6.2] [Reference Citation Analysis]